Skip to main content

Articles

Page 20 of 38

  1. The original article [1] contained an error in Table 1 whereby the ‘Positive’ column in the ‘PD-L1’ Tumor type group of columns was mistakenly included at the beginning of the ‘PD-L2’ Tumor type group of columns.

    Authors: Bingxin Zheng, Tingting Ren, Yi Huang, Kunkun Sun, Shidong Wang, Xing Bao, Kuisheng Liu and Wei Guo
    Citation: Journal of Hematology & Oncology 2018 11:37

    The original article was published in Journal of Hematology & Oncology 2018 11:16

  2. Protein tyrosine phosphatase of regenerating liver 3 (PRL-3) is overexpressed in a subset of AML patients with inferior prognosis, representing an attractive therapeutic target. However, due to relatively shal...

    Authors: Jianbiao Zhou, Sabrina Hui-Min Toh, Zit-Liang Chan, Jessie Yiying Quah, Jing-Yuan Chooi, Tuan Zea Tan, Phyllis S. Y. Chong, Qi Zeng and Wee-Joo Chng
    Citation: Journal of Hematology & Oncology 2018 11:36
  3. Anti-CD19 CAR T cell therapy has demonstrated high response rates in patients with relapsed or refractory (r/r) B cell malignancies but is associated with significant toxicity. Cytokine release syndrome (CRS) ...

    Authors: David Porter, Noelle Frey, Patricia A. Wood, Yanqiu Weng and Stephan A. Grupp
    Citation: Journal of Hematology & Oncology 2018 11:35

    The Correction to this article has been published in Journal of Hematology & Oncology 2018 11:81

  4. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is widely used to treat malignant hematological neoplasms and non-malignant hematological disorders. Approximately, 5000 allo-HSCT procedures are ...

    Authors: Lanping Xu, Hu Chen, Jing Chen, Mingzhe Han, He Huang, Yongrong Lai, Daihong Liu, Qifa Liu, Ting Liu, Ming Jiang, Hanyun Ren, Yongping Song, Zimin Sun, Jianmin Wang, Depei Wu, Daobin Zhou…
    Citation: Journal of Hematology & Oncology 2018 11:33
  5. The use of alkylating agents such as temozolomide in association with radiotherapy (RT) is the therapeutic standard of glioblastoma (GBM). This regimen modestly prolongs overall survival, also if, in light of ...

    Authors: Claudio Festuccia, Andrea Mancini, Alessandro Colapietro, Giovanni Luca Gravina, Flora Vitale, Francesco Marampon, Simona Delle Monache, Simona Pompili, Loredana Cristiano, Antonella Vetuschi, Vincenzo Tombolini, Yi Chen and Thomas Mehrling
    Citation: Journal of Hematology & Oncology 2018 11:32

    The Correction to this article has been published in Journal of Hematology & Oncology 2018 11:38

  6. We recently identified the human leukocyte immunoglobulin-like receptor B2 (LILRB2) and its mouse ortholog-paired Ig-like receptor (PirB) as receptors for several angiopoietin-like proteins (Angptls). We also ...

    Authors: Xunlei Kang, Changhao Cui, Chen Wang, Guojin Wu, Heyu Chen, Zhigang Lu, Xiaoli Chen, Li Wang, Jie Huang, Huimin Geng, Meng Zhao, Zhengshan Chen, Markus Müschen, Huan-You Wang and Cheng Cheng Zhang
    Citation: Journal of Hematology & Oncology 2018 11:30
  7. Although current chemotherapy using bortezomib (Velcade) against multiple myeloma in adults has achieved significant responses and even remission, a majority of patients will develop acquired resistance to bor...

    Authors: Zhihong Zheng, Shengjun Fan, Jing Zheng, Wei Huang, Cristina Gasparetto, Nelson J. Chao, Jianda Hu and Yubin Kang
    Citation: Journal of Hematology & Oncology 2018 11:29
  8. This study was performed to investigate the role of nucleotide-binding oligomerization domain (NOD)-like receptor X1 (NLRX1) in regulating hepatocellular carcinoma (HCC) progression.

    Authors: Bo Hu, Guang-Yu Ding, Pei-Yao Fu, Xiao-Dong Zhu, Yuan Ji, Guo-Ming Shi, Ying-Hao Shen, Jia-Bin Cai, Zhen Yang, Jian Zhou, Jia Fan, Hui-Chuan Sun, Ming Kuang and Cheng Huang
    Citation: Journal of Hematology & Oncology 2018 11:28
  9. Adenosine triphosphate (ATP)-dependent chromatin remodeling SWI/SNF-like BAF and PBAF complexes have been implicated in the regulation of stem cell function and cancers. Several subunits of BAF or PBAF, includ...

    Authors: Lulu Liu, Xiaoling Wan, Peipei Zhou, Xiaoyuan Zhou, Wei Zhang, Xinhui Hui, Xiujie Yuan, Xiaodan Ding, Ruihong Zhu, Guangxun Meng, Hui Xiao, Feng Ma, He Huang, Xianmin Song, Bin Zhou, Sidong Xiong…
    Citation: Journal of Hematology & Oncology 2018 11:27
  10. Resistance to tamoxifen (TAM) frequently occurs in the treatment of estrogen receptor positive (ER+) breast cancer. Accumulating evidences indicate that transcription factor HOXB13 is of great significance in ...

    Authors: Bowen Liu, Tianjiao Wang, Huawei Wang, Lu Zhang, Feifei Xu, Runping Fang, Leilei Li, Xiaoli Cai, Yue Wu, Weiying Zhang and Lihong Ye
    Citation: Journal of Hematology & Oncology 2018 11:26
  11. Anti-CD19 chimeric antigen receptor (CAR) T cells have shown promise in the treatment of B cell acute lymphocytic leukemia (B-ALL). However, its efficacy in B-ALL patients with extramedullary involvement is li...

    Authors: Jianyu Weng, Peilong Lai, Le Qin, Yunxin Lai, Zhiwu Jiang, Chenwei Luo, Xin Huang, Suijing Wu, Dan Shao, Chengxin Deng, Lisi Huang, Zesheng Lu, Maohua Zhou, Lingji Zeng, Dongmei Chen, Yulian Wang…
    Citation: Journal of Hematology & Oncology 2018 11:25

    The Correction to this article has been published in Journal of Hematology & Oncology 2019 12:117

  12. GARP (glycoprotein-A repetitions predominant) is a type I transmembrane cell surface docking receptor for latent transforming growth factor-β (TGF-β) that is abundantly expressed on regulatory T lymphocytes an...

    Authors: Alessandra Metelli, Mohammad Salem, Caroline H. Wallace, Bill X. Wu, Anqi Li, Xue Li and Zihai Li
    Citation: Journal of Hematology & Oncology 2018 11:24
  13. Although chemo-immunotherapy has led to an improved overall survival for most B-cell lymphoma types, relapsed and refractory disease remains a challenge. The malaria drug artesunate has previously been identif...

    Authors: Thea Kristin Våtsveen, Marit Renée Myhre, Chloé Beate Steen, Sébastien Wälchli, Ole Christian Lingjærde, Baoyan Bai, Pierre Dillard, Theodossis A. Theodossiou, Toril Holien, Anders Sundan, Else Marit Inderberg, Erlend B. Smeland, June Helen Myklebust and Morten P. Oksvold
    Citation: Journal of Hematology & Oncology 2018 11:23
  14. Recently, the US Food and Drug Administration (FDA) approved the first chimeric antigen receptor T cell (CAR-T) therapy for the treatment CD19-positive B cell acute lymphoblastic leukemia. While CAR-T has achi...

    Authors: Jian Li, Wenwen Li, Kejia Huang, Yang Zhang, Gary Kupfer and Qi Zhao
    Citation: Journal of Hematology & Oncology 2018 11:22
  15. In recent years, circular RNAs (circRNAs) have attracted considerable attention because they play a significant role in many fields of cancer biology. Additionally, it has become increasingly clear that circRN...

    Authors: Miaoci Zhang and Yan Xin
    Citation: Journal of Hematology & Oncology 2018 11:21
  16. Patient-derived xenograft (PDX) models with definite molecular signature are attractive preclinical models for development of novel targeted drugs. Here, we profiled and explored potential therapeutic targets ...

    Authors: Zuhua Chen, Wenwen Huang, Tiantian Tian, Wanchun Zang, Jingyuan Wang, Zhentao Liu, Zhongwu Li, Yumei Lai, Zhi Jiang, Jing Gao and Lin Shen
    Citation: Journal of Hematology & Oncology 2018 11:20
  17. SF3B1 is a core component of splicing machinery. Mutations in SF3B1 are frequently found in myelodysplastic syndromes (MDS), particularly in patients with refractory anemia with ringed sideroblasts (RARS), cha...

    Authors: Yumin Huang, John Hale, Yaomei Wang, Wei Li, Shijie Zhang, Jieying Zhang, Huizhi Zhao, Xinhua Guo, Jing Liu, Hongxia Yan, Karina Yazdanbakhsh, Gang Huang, Christopher D. Hillyer, Narla Mohandas, Lixiang Chen, Ling Sun…
    Citation: Journal of Hematology & Oncology 2018 11:19
  18. Racial and ethnic disparities in malignancies attract extensive attention. To investigate whether there are racial and ethnic disparities in genetic alteration between Caucasian and Eastern Asian population, d...

    Authors: Hui Wei, Ying Wang, Chunlin Zhou, Dong Lin, Bingcheng Liu, Kaiqi Liu, Shaowei Qiu, Benfa Gong, Yan Li, Guangji Zhang, Shuning Wei, Xiaoyuan Gong, Yuntao Liu, Xingli Zhao, Runxia Gu, Yingchang Mi…
    Citation: Journal of Hematology & Oncology 2018 11:18
  19. Chromobox protein homolog 7 (CBX7), a member of the polycomb group (PcG) family of proteins, is involved in the regulation of cell proliferation and cancer progression. PcG family members, such as BMI, Mel-18,...

    Authors: Su-Jie Ni, Li-Qin Zhao, Xiao-Feng Wang, Zhen-Hua Wu, Rui-Xi Hua, Chun-Hua Wan, Jie-Yun Zhang, Xiao-Wei Zhang, Ming-Zhu Huang, Lu Gan, Hua-Lin Sun, Goberdhan P. Dimri and Wei-Jian Guo
    Citation: Journal of Hematology & Oncology 2018 11:17
  20. Immune checkpoint inhibitors have led to a breakthrough in solid tumor immunotherapy, but related studies on musculoskeletal tumors are few, especially for PD-L2.

    Authors: Bingxin Zheng, Tingting Ren, Yi Huang, Kunkun Sun, Shidong Wang, Xing Bao, Kuisheng Liu and Wei Guo
    Citation: Journal of Hematology & Oncology 2018 11:16

    The Correction to this article has been published in Journal of Hematology & Oncology 2018 11:37

  21. Natural killer/T-cell lymphoma (NKTCL) is a rare subtype of non-Hodgkin lymphoma that is associated with a poor outcome. Currently, the treatment needs of NKTCL remain unmet, and efforts to further improve tre...

    Authors: Xin Li, Yasong Cheng, Mingzhi Zhang, Jiaqin Yan, Ling Li, Xiaorui Fu, Xudong Zhang, Yu Chang, Zhenchang Sun, Hui Yu, Lei Zhang, Xinhua Wang, Jingjing Wu, Zhaoming Li, Feifei Nan, Li Tian…
    Citation: Journal of Hematology & Oncology 2018 11:15
  22. A poor prognosis of pancreatic ductal adenocarcinoma (PDAC) associated with chemoresistance has not changed for the past three decades. A multidisciplinary diagnosis followed by surgery and chemo(radiation)the...

    Authors: Yiyin Zhang, Chao Yang, He Cheng, Zhiyao Fan, Qiuyi Huang, Yu Lu, Kun Fan, Guopei Luo, Kaizhou Jin, Zhengshi Wang, Chen Liu and Xianjun Yu
    Citation: Journal of Hematology & Oncology 2018 11:14
  23. Mantle cell lymphoma (MCL) is a rare and incurable subtype of non-Hodgkin’s lymphoma that generally affects older individuals. However, the use of high-dose therapy and autologous stem cell transplant has impr...

    Authors: Raphael E. Steiner, Jorge Romaguera and Michael Wang
    Citation: Journal of Hematology & Oncology 2018 11:13
  24. High frequency of recurrence is the major cause of the poor outcomes for patients with hepatocellular carcinoma (HCC). microRNA (miR)-182-5p emerged as a high-priority miRNA in HCC and was found to be related ...

    Authors: Man-Qing Cao, A-Bin You, Xiao-Dong Zhu, Wei Zhang, Yuan-Yuan Zhang, Shi-Zhe Zhang, Ke-wei Zhang, Hao Cai, Wen-Kai Shi, Xiao-Long Li, Kang-Shuai Li, Dong-Mei Gao, De-Ning Ma, Bo-Gen Ye, Cheng-Hao Wang, Cheng-Dong Qin…
    Citation: Journal of Hematology & Oncology 2018 11:12

    The Correction to this article has been published in Journal of Hematology & Oncology 2018 11:56

  25. Despite the high cure rate of T cell acute lymphoblastic leukemia (T-ALL), drug resistance to chemotherapy remains a significant clinical problem. Bone marrow mesenchymal stem cells (MSCs) protect leukemic cel...

    Authors: Jiancheng Wang, Xin Liu, Yuan Qiu, Yue Shi, Jianye Cai, Boyan Wang, Xiaoyue Wei, Qiong Ke, Xin Sui, Yi Wang, Yinong Huang, Hongyu Li, Tao Wang, Ren Lin, Qifa Liu and Andy Peng Xiang
    Citation: Journal of Hematology & Oncology 2018 11:11
  26. Solitary plasmacytoma is an infrequent form of plasma cell dyscrasia that presents as a single mass of monoclonal plasma cells, located either extramedullary or intraosseous. In some patients, a bone marrow as...

    Authors: J. Caers, B. Paiva, E. Zamagni, X. Leleu, J. Bladé, S. Y. Kristinsson, C. Touzeau, N. Abildgaard, E. Terpos, R. Heusschen, E. Ocio, M. Delforge, O. Sezer, M. Beksac, H. Ludwig, G. Merlini…
    Citation: Journal of Hematology & Oncology 2018 11:10
  27. The influences of oncogenic Ezh2 on the progression and prognosis of gastric cancer (GC) and the underlying mechanisms are still poorly understood. Here, we aimed at investigating clinicopathological significa...

    Authors: Lu Gan, Midie Xu, Ruixi Hua, Cong Tan, Jieyun Zhang, Yiwei Gong, Zhenhua Wu, Weiwei Weng, Weiqi Sheng and Weijian Guo
    Citation: Journal of Hematology & Oncology 2018 11:9
  28. Malignant cells have the capacity to rapidly grow exponentially and spread in part by suppressing, evading, and exploiting the host immune system. Immunotherapy is a form of oncologic treatment directed toward...

    Authors: Julian A. Marin-Acevedo, Aixa E. Soyano, Bhagirathbhai Dholaria, Keith L. Knutson and Yanyan Lou
    Citation: Journal of Hematology & Oncology 2018 11:8
  29. Acute myeloid leukemia (AML) is one of the most common types of adult acute leukemia. Standard chemotherapies can induce complete remission in selected patients; however, a majority of patients eventually rela...

    Authors: Jinghua Wang, Siyu Chen, Wei Xiao, Wende Li, Liang Wang, Shuo Yang, Weida Wang, Liping Xu, Shuangye Liao, Wenjian Liu, Yang Wang, Nawei Liu, Jianeng Zhang, Xiaojun Xia, Tiebang Kang, Gong Chen…
    Citation: Journal of Hematology & Oncology 2018 11:7
  30. The original article [1] contained incorrect affiliations for the authors.

    Authors: Chun-Hua Wei, Gang Wu, Qian Cai, Xi-Can Gao, Fan Tong, Rui Zhou, Rui-Guang Zhang, Ji-Hua Dong, Yu Hu and Xiao-Rong Dong
    Citation: Journal of Hematology & Oncology 2018 11:6

    The original article was published in Journal of Hematology & Oncology 2017 10:125

  31. The original article [1] contains two errors in Table 2

    Authors: Xinyang Liu, Shukui Qin, Zhichao Wang, Jianming Xu, Jianping Xiong, Yuxian Bai, Zhehai Wang, Yan Yang, Guoping Sun, Liwei Wang, Leizhen Zheng, Nong Xu, Ying Cheng, Weijian Guo, Hao Yu, Tianshu Liu…
    Citation: Journal of Hematology & Oncology 2018 11:5

    The original article was published in Journal of Hematology & Oncology 2017 10:153

  32. Novel therapies for patients with acute myeloid leukemia (AML) are imperative, particularly for those with high-risk features. Selinexor, an exportin 1 (XPO1/CRM1) inhibitor, has demonstrated anti-leukemia act...

    Authors: Amy Y. Wang, Howard Weiner, Margaret Green, Hua Chang, Noreen Fulton, Richard A. Larson, Olatoyosi Odenike, Andrew S. Artz, Michael R. Bishop, Lucy A. Godley, Michael J. Thirman, Satyajit Kosuri, Jane E. Churpek, Emily Curran, Kristen Pettit, Wendy Stock…
    Citation: Journal of Hematology & Oncology 2018 11:4
  33. Acute myeloid leukemia (AML) is a molecularly and clinically heterogeneous disease. Despite advances in understanding the pathogenesis of AML, the standard therapy remained nearly unchanged over the past three...

    Authors: Xue Yang and Jianxiang Wang
    Citation: Journal of Hematology & Oncology 2018 11:3
  34. The authors have retracted this article [1] because of significant overlap of text and some images with a previously published article by Xu et al. [2]. A formal investigation by the 1st Affiliated Hospital of...

    Authors: Yu Fan, Yan-fen Wang, Hua-fang Su, Na Fang, Chen Zou, Wen-feng Li and Zheng-hua Fei
    Citation: Journal of Hematology & Oncology 2018 11:2

    The original article was published in Journal of Hematology & Oncology 2016 9:57

  35. Chimeric antigen receptor (CAR)-engineered T cells have demonstrated promising clinical efficacy in patients with B cell lymphoma. However, the application of CAR-T cell therapy in the treatment of other solid...

    Authors: Jiayi Yu, Xiaowen Wu, Junya Yan, Huan Yu, Longwen Xu, Zhihong Chi, Xinan Sheng, Lu Si, Chuanliang Cui, Jie Dai, Meng Ma, Tianxiao Xu, Yan Kong and Jun Guo
    Citation: Journal of Hematology & Oncology 2018 11:1
  36. Liquid biopsy especially that of exosomes carries tumor-specific molecules and provides useful information during tumor development and progression in “real time.” Exosomes are membrane-encapsulated vesicles, ...

    Authors: Aichun Li, Tianbao Zhang, Min Zheng, Yanning Liu and Zhi Chen
    Citation: Journal of Hematology & Oncology 2017 10:175
  37. Liposarcoma, the most common soft tissue tumor, is understudied cancer, and limited progress has been made in the treatment of metastatic disease. The Achilles heel of cancer often is their kinases that are ex...

    Authors: Deepika Kanojia, Manoj Garg, Jacqueline Martinez, Anand M.T., Samuel B. Luty, Ngan B. Doan, Jonathan W. Said, Charles Forscher, Jeffrey W. Tyner and H. Phillip Koeffler
    Citation: Journal of Hematology & Oncology 2017 10:173
  38. The tyrosine kinase Src is involved in the progression of many cancers. Moreover, inhibiting Src activity has been shown to obstruct several signaling pathways regulated by the EGFR. Thus, Src is a valuable ta...

    Authors: Yi-Hua Lai, Sih-Yin Lin, Yu-Shan Wu, Huei-Wen Chen and Jeremy J. W. Chen
    Citation: Journal of Hematology & Oncology 2017 10:172
  39. The observational MCL-004 study evaluated outcomes in patients with relapsed/refractory mantle cell lymphoma who received lenalidomide-based therapy after ibrutinib failure or intolerance.

    Authors: Michael Wang, Stephen J. Schuster, Tycel Phillips, Izidore S. Lossos, Andre Goy, Simon Rule, Mehdi Hamadani, Nilanjan Ghosh, Craig B. Reeder, Evelyn Barnett, Marie-Laure Casadebaig Bravo and Peter Martin
    Citation: Journal of Hematology & Oncology 2017 10:171
  40. Cholangiocarcinoma (CCA) is characterized by early lymphatic, metastasis, and low survival rate. Epithelial-mesenchymal transition (EMT) is able to induce tumor metastasis. Although the TGF-β/miR-200 signals p...

    Authors: Dawei Zhang, Haiyan Li, Xiaofeng Jiang, Liangqi Cao, Zilong Wen, Xuewei Yang and Ping Xue
    Citation: Journal of Hematology & Oncology 2017 10:170
  41. The molecular mechanisms underlying dysregulated wild type (wt) p53 in multiple myeloma (MM) have been subjects of intense investigation for years. Indeed, correlation of rarely occurring TP53 gene mutations or d...

    Authors: Jahangir Abdi, Nasrin Rastgoo, Lihong Li, Wenming Chen and Hong Chang
    Citation: Journal of Hematology & Oncology 2017 10:169
  42. Nuclear receptors (NRs) can regulate gene expression; therefore, they are classified as transcription factors. Despite the extensive research carried out on NRs, still several issues including (1) the expressi...

    Authors: Luqiao Wang, Gayani Nanayakkara, Qian Yang, Hongmei Tan, Charles Drummer, Yu Sun, Ying Shao, Hangfei Fu, Ramon Cueto, Huimin Shan, Teodoro Bottiglieri, Ya-feng Li, Candice Johnson, William Y. Yang, Fan Yang, Yanjie Xu…
    Citation: Journal of Hematology & Oncology 2017 10:168
  43. Novel immunotherapeutic agents targeting tumor-site microenvironment are revolutionizing cancer therapy. Chimeric antigen receptor (CAR)-engineered T cells are widely studied for cancer immunotherapy. CD19-spe...

    Authors: Bingshan Liu, Yongping Song and Delong Liu
    Citation: Journal of Hematology & Oncology 2017 10:166
  44. T cells recognize antigen fragments from proteolytic products that are presented to them in the form of peptides on major histocompatibility complex (MHC) molecules, which is crucial for the T cell to identify...

    Authors: Liangshun You, Liping Mao, Juying Wei, Shenhe Jin, Chunmei Yang, Hui Liu, Li Zhu and Wenbin Qian
    Citation: Journal of Hematology & Oncology 2017 10:165
  45. Mantle cell lymphoma (MCL) is characterized by an aggressive clinical course and secondary resistance to currently available therapies in most cases. Therefore, despite recent advances in the treatment of this...

    Authors: Michael Fichtner, Martin Dreyling, Mascha Binder and Martin Trepel
    Citation: Journal of Hematology & Oncology 2017 10:164

Annual Journal Metrics

  • 2022 Citation Impact
    28.5 - 2-year Impact Factor
    23.1 - 5-year Impact Factor
    4.045 - SNIP (Source Normalized Impact per Paper)
    6.046 - SJR (SCImago Journal Rank)

    2023 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    59 days submission to accept (Median)

    2023 Usage 
    3,173,795 downloads
    2,671 Altmetric mentions

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here